Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs
Harbour BioMed And Jacobio Went Public In Hong Kong
Executive Summary
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
You may also be interested in...
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Finance Watch: Inhibikase IPO Brought 2020 US Total To 86
Public Company Edition: The new year started with two companies signaling plans for significant near-term initial public offerings, following Inhibikase’s launch as the last IPO of 2020. Other recent financial highlights include layoffs at Calithera and Regenxbio’s $200m Zolgensma royalty sale.
Filing Imminent As Mycovia’s Antifungal Prevents Recurrent Vulvovaginal Candidiasis
Oteseconazole prevented recurrent VVC in two Phase III studies but Phase III data in acute treatment of VVC episodes in women with RVVC, also due this month, are needed to file for US FDA approval in the first half of 2021.